CoLucid Pharmaceuticals (United States)

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

Peter J. Goadsby, Linda Wietecha, Ellen B. Dennehy et al. · Brain · 2019 · 264 citations · Full text

Acute Treatment, Pain Medicine, Psychopharmacology +16

Lasmiditan is an effective acute treatment for migraine

Bernice Kuca, Stephen D. Silberstein, Linda Wietecha et al. · Neurology · 2018 · 260 citations · Full text

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

Hans‐Christoph Diener, Gilles Géraud, Miguel J. A. Láinez et al. · The Lancet Neurology · 2012 · 186 citations

Acute Treatment, Cluster Headache, Medicine +6

Characterization of binding, functional activity, and contractile responses of the selective 5‐HT_1F receptor agonist lasmiditan

Eloísa Rubio‐Beltrán, Alejandro Labastida‐Ramírez, Kristian Agmund Haanes et al. · British Journal of Pharmacology · 2019 · 71 citations · Full text

Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine (S50.008)

Linda Wietecha, Bernice Kuca, Josephine Asafu‐Adjei et al. · Neurology · 2018 · 13 citations

Acute Treatment, Cluster Headache, Safety Findings +6